The lawsuit, filed by Rosen Law Firm, claims that ARS Pharmaceuticals provided investors with misleading information concerning the rollout of expanded insurance coverage for its epinephrine nasal spray, neffy, through CVS Caremark. According to the complaint, defendants expressed confidence that coverage would commence on July 1, 2026, in time for peak allergy seasons, while allegedly concealing adverse facts about the actual timeline. This discrepancy purportedly led to the purchase of shares at artificially inflated prices.

Investors who acquired securities during the specified Class Period may be eligible for compensation through a contingency fee arrangement. While the court has not yet certified a class, those interested in serving as lead plaintiff must submit their motions by October 5, 2026. Participation as a lead plaintiff is not required to be eligible for potential future recoveries, and investors retain the right to select their own legal counsel or remain absent class members.